References of "Expert Opinion on Therapeutic Patents"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailAMPA receptor positive allosteric modulators: a patent review
Pirotte, Bernard ULg; Francotte, Pierre ULg; Goffin, Eric ULg et al

in Expert Opinion on Therapeutic Patents (2013), 23

Detailed reference viewed: 18 (3 ULg)
Full Text
Peer Reviewed
See detailNovel dipyrazoles acting as glutamate modulators
Francotte, Pierre ULg; De Tullio, Pascal ULg; Pirotte, Bernard ULg

in Expert Opinion on Therapeutic Patents (2007), 17(12), 1489-1493

Knowing the potential therapeutic interest of AMPA potentiation, patents have been published for 15 years relating the discovery of novel compounds able to allosterically bind to the AMPA receptors and ... [more ▼]

Knowing the potential therapeutic interest of AMPA potentiation, patents have been published for 15 years relating the discovery of novel compounds able to allosterically bind to the AMPA receptors and leading to a potentiation of the AMPA signals. Besides this classical approach, a new target for the medicinal chemist has been defined due to the recent findings describing the modulation of AMPA receptors by neuronal proteins, and has led to the design of dipyrazole compounds by Aventis. These new dipyrazole derivatives may be considered as `indirect AMPApams', constituting a new pharmacological class. Based on their in vitro activity, it is probable that these compounds could be of therapeutic value for the treatment of cognitive disorders, schizophrenia or depression. [less ▲]

Detailed reference viewed: 40 (16 ULg)
Full Text
Peer Reviewed
See detailNew insights into the development pf ATP-sensitive potassium channel openers
Pirotte, Bernard ULg; De Tullio, Pascal ULg; Antoine, M.-H. et al

in Expert Opinion on Therapeutic Patents (2005), 15

Detailed reference viewed: 16 (1 ULg)
Full Text
Peer Reviewed
See detailUpdate on GPIIb/IIIa antagonists
Hanson, Julien ULg; De Leval, X.; Kolh, Philippe ULg et al

in Expert Opinion on Therapeutic Patents (2003), 13

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailRecent developments in 5-lipoxygenase inhibitors
Julémont, F.; Dogné, J.-M.; Laeckmann, D. et al

in Expert Opinion on Therapeutic Patents (2003), 13

Detailed reference viewed: 7 (2 ULg)
Full Text
Peer Reviewed
See detailThe inhibition of metalloproteinases to treat osteoarthritis: reality and new perspectives
Henrotin, Yves ULg; Sanchez, Christelle ULg; Reginster, Jean-Yves ULg

in Expert Opinion on Therapeutic Patents (2002), 12(1), 29-43

The objective of this paper is to analyse the potential therapeutic action of MMP inhibitors in the management of osteoarthritis (OA), based on a critical review of the literature. The role played by ... [more ▼]

The objective of this paper is to analyse the potential therapeutic action of MMP inhibitors in the management of osteoarthritis (OA), based on a critical review of the literature. The role played by metalloproteinases (MPs) in the pathophysiology of osteoarthritis is discussed, as well as their regulation by tissular inhibitors, activators and cytokines. The evidences that commonly used drugs for treating osteoarthritis are also active on MPs synthesis is also reported. Finally, this paper provides an analysis of the recent patents published with promising therapeutic potential and gives new perspectives for anti-MPs therapy. [less ▲]

Detailed reference viewed: 22 (6 ULg)
Full Text
Peer Reviewed
See detailAdvances in the field of COX-2 inhibition
De Leval, X.; Julémont, F.; Delarge, J. et al

in Expert Opinion on Therapeutic Patents (2002), 12

Detailed reference viewed: 4 (1 ULg)
Full Text
Peer Reviewed
See detailLatest discoveries in prostaglandin receptor modulators
Benoit, P.; De Leval, X.; Pirotte, Bernard ULg et al

in Expert Opinion on Therapeutic Patents (2002), 12

Detailed reference viewed: 4 (0 ULg)